No Detail Found!

Predictors of Nucleos(t)ide Analogues Discontinuation Relapse: Hepatitis B Virus RNA versus Hepatitis B Surface Antigen

Author(s)
Shuo Wu Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University, Jinan, China; Department of Gastroenterology, Hospital of Traditional Chinese Medicine of Linyi City, Linyi, China
Tao Li Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University,Jinan,China
Feng Liu Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University,Jinan,China
Dedong Yin Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University,Jinan,China
Lixin Zhang Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University,Jinan,China
Lei Wang Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University,Jinan,China
Abstract
Objective: To compare the predictive value of hepatitis B virus (HBV) RNA and HBsAg quanti cation upon discontinuation of nucleos(t)ide analogues (NAs) therapy for clinical and virological relapse in chronic hepatitis B (CHB). Study Design: Observational study. Place and Duration of the Study: Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University, Jinan, China, from July 2014 to December 2020. Methodology: CHB patients received single NAs and discontinued treatment following appropriate standards. HBsAg quanti cation was conducted using the i2000 Chemiluminescent Immunoassay (CLIA) Analyser, while serum HBV RNA quanti cation was performed using speci c RNA target capture and simultaneous ampli cation and testing. The main observational endpoints included virological relapse and clinical relapse. Results: Eighty-one patients were recruited, with 15 patients achieving HBsAg loss at cessation. Twenty-nine individuals encountered virological relapse, while 13 patients experienced clinical relapse. Thirty-one patients achieved HBsAg <100 IU/ml at NAs cessation, among whom 26 achieved undetectable HBV RNA, while four patients su ered virological relapse (15.4%). Serum HBV RNA emerged as an independent determinant of virological relapse (HR 1.850), clinical relapse (HR 2.020), and HBsAg loss after NAs cessation (HR 0.138). The presence of HBsAg <100 IU/ml at cessation did not serve as a predictor for virological relapse and clinical relapse. Conclusion: Lower HBV RNA levels predict a better o -treatment response. Discontinuation of prolonged NAs therapy appears as a viable and safe choice for patients with undetectable HBV RNA. In comparison to HBV RNA, HBsAg <100 IU/ml at cessation did not show su cient predictive value for virological relapse and clinical relapse.
Publication Details
Page(s) 545-550
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 5, Year: 2024

Request the full text from PASTIC

Keywords
Relapse, Hepatitis B Surface Antigen, Chronic hepatitis B, HBV RNA
0

Citations

0

Downloads

82

Views